A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin.
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2014
At a glance
- Drugs Glutathione/inosine (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cellectar Biosciences
- 11 Feb 2014 Novelos Therapeutics now known as Cellectar Biosciences
- 12 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Mar 2010 Status changed from not yet recruiting to recruiting, according to a media release from Novelos Therapeutics.